AU2001282373A1 - Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion - Google Patents

Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion

Info

Publication number
AU2001282373A1
AU2001282373A1 AU2001282373A AU8237301A AU2001282373A1 AU 2001282373 A1 AU2001282373 A1 AU 2001282373A1 AU 2001282373 A AU2001282373 A AU 2001282373A AU 8237301 A AU8237301 A AU 8237301A AU 2001282373 A1 AU2001282373 A1 AU 2001282373A1
Authority
AU
Australia
Prior art keywords
proanthocyanidins
stimulator
arginine
salts
source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282373A
Other languages
English (en)
Inventor
Victor Ferrari
Peter Rohdewald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horphag Research Ltd
Original Assignee
Horphag Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horphag Research Ltd filed Critical Horphag Research Ltd
Publication of AU2001282373A1 publication Critical patent/AU2001282373A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001282373A 2000-05-26 2001-05-24 Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion Abandoned AU2001282373A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20752000P 2000-05-26 2000-05-26
US60/207,520 2000-05-26
PCT/IB2001/000910 WO2001089543A2 (en) 2000-05-26 2001-05-24 Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion

Publications (1)

Publication Number Publication Date
AU2001282373A1 true AU2001282373A1 (en) 2001-12-03

Family

ID=22770931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282373A Abandoned AU2001282373A1 (en) 2000-05-26 2001-05-24 Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion

Country Status (4)

Country Link
US (2) US6565851B2 (https=)
JP (1) JP2003534286A (https=)
AU (1) AU2001282373A1 (https=)
WO (1) WO2001089543A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171030A1 (en) * 2000-05-26 2005-08-04 Peter Rohdewald Relieving symptoms of erectile dysfunction and attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
US20040137081A1 (en) * 2003-01-13 2004-07-15 Peter Rohdewald Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
WO2001089543A2 (en) * 2000-05-26 2001-11-29 Horphag Research Limited Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
JP2003334022A (ja) * 2002-05-17 2003-11-25 Toyo Shinyaku:Kk 持久力向上用食品組成物
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
WO2005107735A2 (en) * 2004-04-30 2005-11-17 Pump Formulations, Ltd. Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a
US20080089962A1 (en) * 2004-09-24 2008-04-17 Multi Formulations Ltd. Nutritional composition for facilitating muscle pumps
HUP0401422A2 (en) 2004-07-15 2006-04-28 G Laszlo Meszaros Use of l-arginine as vasoaktive ingredient absorbing through skin for external application
JP2010163426A (ja) * 2008-12-18 2010-07-29 Daiichi Sankyo Healthcare Co Ltd ホスホジエステラーゼ５阻害剤とアルギニンを含有する医薬組成物
BR112012032632A2 (pt) 2010-06-25 2016-11-22 Horphag Res Ip Pre Ltd composição para melhorar o vigor sexual
IT1402672B1 (it) * 2010-11-08 2013-09-13 Medestea Biotech S P A Composizioni comprendenti principi attivi di origine vegetale associati o meno a promotori e/o protettori di ossido nitrico per il trattamento e la prevenzione dei deficit erettili e dell' impotenza e per il potenziamento della performance sportiva
RU2458537C1 (ru) * 2011-03-14 2012-08-20 Общество С Ограниченной Ответственностью "Парафарм" Биологически активная добавка к пище для профилактики эректильной дисфункции у мужчин
JP2014156429A (ja) * 2013-02-15 2014-08-28 Toyo Shinyaku Co Ltd エンドセリン受容体発現抑制剤
LT6262B (lt) 2014-05-16 2016-04-25 Uab "Ekologiå Ka Energija" Tonizuojantis gėrimas moterims ir vyrams
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2020165917A1 (en) * 2019-02-11 2020-08-20 Olene Life Sciences Private Limited A synergistic herbal composition for sexual disorders
JP2020164495A (ja) * 2019-03-29 2020-10-08 株式会社東洋新薬 男性活力用組成物及び組成物
PT4164629T (pt) * 2020-06-18 2024-08-02 Horphag Res Management Sa Procianidinas para o tratamento da disfunção endotelial desencadeada pela covid-19

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5695761A (en) * 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
US6469053B1 (en) * 1996-04-02 2002-10-22 Mars Incorporated Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6423743B1 (en) * 1996-04-02 2002-07-23 Mars Incorporated Cocoa extract compounds and methods for making and using the same
US5720956A (en) 1996-04-10 1998-02-24 Rohdewald; Peter Method of controlling the reactivity of human blood platelets by oral administration of the extract of the maritime pine (pycnogenol)
US6558713B2 (en) * 1996-09-06 2003-05-06 Mars, Incorporated Health of a mammal by administering a composition containing at least one cocoa polyphenol ingredient
FR2765483B1 (fr) * 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
PL342857A1 (en) * 1998-03-12 2001-07-16 Mars Inc Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
US8507018B2 (en) * 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
DE19845314B4 (de) 1998-10-01 2008-01-17 Horphag Research (Luxembourg) Holding Sa Procyanidinhaltiges Mittel zur Behandlung von erektiler Dysfunktion
JP3260134B2 (ja) * 1999-10-08 2002-02-25 信孝 鈴木 月経困難症、子宮内膜症の治療薬
RU2303373C2 (ru) * 2000-04-14 2007-07-27 Марс, Инкорпорейтед Композиции и способы улучшения состояния сосудистой системы
WO2001089543A2 (en) * 2000-05-26 2001-11-29 Horphag Research Limited Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
US6706756B1 (en) * 2001-11-16 2004-03-16 University Of South Florida Vasodilating compound and method of use

Also Published As

Publication number Publication date
WO2001089543A2 (en) 2001-11-29
US20020037862A1 (en) 2002-03-28
US6565851B2 (en) 2003-05-20
WO2001089543A3 (en) 2002-10-03
JP2003534286A (ja) 2003-11-18
US20030104077A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2001282373A1 (en) Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
WO2000045801A3 (en) Use of a nitrate vasodilator alone or in combination with capsaicin for the treatment of pain
BR0113890A (pt) Derivados de ácido hexenóico e 2-amino-2-alquil-4 hexenóico úteis como inibidores de sintase de óxido nìtrico
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
IL157208A0 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
MY136173A (en) 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
AU2001286562A1 (en) Use of agaricus blazei murill to prevent or treat skin and other disorders
WO2004000293A3 (fr) Utilisation de la taurine ou de derives pour le traitement de l'alopecie
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
GB2456475A (en) Composition for the treatment of skin conditions
AU2002346594A1 (en) Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
HUP0400924A3 (en) Use of 2,5-dihydroxybenzenesulfphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
AU2002228660A1 (en) Use of amidoamines to treat or prevent acanthamoeba and fungal infections
MXPA05005911A (es) Utilizacion del acido docosahexaenoico como sustancia activa para el tratamiento de la lipodistrofia.
GB0003201D0 (en) Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
AU2002348299A8 (en) Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
PL350413A1 (en) Pharmaceutical effervescent formulation containing metamizol
AU2003244885A1 (en) Oral delivery of biological active agents in a nanoemulsion formulation to the human body
EP1048294A3 (en) Use of a nitrate vasodilator alone or in combination with capsaicin for the treatment of pain
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction